Sunesis Pharmaceuticals (FRA:RYIS) Price-to-Tangible-Book : 24.92 (As of May. 11, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-11), Sunesis Pharmaceuticals's share price is €16.275016. Sunesis Pharmaceuticals's Tangible Book per Share of Dec. 2020 for the quarter that ended in Dec. 2020 was €0.65. Hence, Sunesis Pharmaceuticals's Price to Tangible Book Ratio of today is 24.92.

The historical rank and industry rank for Sunesis Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

FRA:RYIS's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.7
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Sunesis Pharmaceuticals's share price is €16.275016. Sunesis Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2020 was €0.65. Hence, Sunesis Pharmaceuticals's P/B Ratio of today is 24.92.

Sunesis Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Sunesis Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Price-to-Tangible-Book Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Price-to-Tangible-Book

Get a 7-Day Free Trial

117.41

729.65

8.79

8.01

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Price-to-Tangible-Book	Get a 7-Day Free Trial															8.79	14.95	23.33	4.36	8.01

Competitive Comparison of Sunesis Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunesis Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Price-to-Tangible-Book falls into.

Sunesis Pharmaceuticals Price-to-Tangible-Book Calculation

Sunesis Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2020 )
	=	16.275016	/	0.653
	=	24.92

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Sunesis Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines